Anti-infectivity of camel polyclonal antibodies against hepatitis C virus in Huh7.5 hepatoma

Virology Journal

Volumn 9, Issue , 2012, Pages

  El Fakharany, Esmail M ^a   Abedelbaky, Nawal ^a   Haroun, Bakry M ^b   Sánchez, Lourdes ^c   Redwan, Nezar A ^d   Redwan, Elrashdy M ^a,d  

^a Universities and Research centers District   (Egypt)

^b AL AZHAR UNIVERSITY   (Egypt)

^c UNIVERSIDAD DE ZARAGOZA   (Spain)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Camel milk proteins; Hepatitis C virus; Infectivity; Screening

Indexed keywords

ALPHA LACTALBUMIN; CASEIN; IMMUNOGLOBULIN G ANTIBODY; LACTOFERRIN; MILK PROTEIN; POLYCLONAL ANTIBODY; SYNTHETIC PEPTIDE; VIRUS ANTIBODY;

ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; CAMEL; CELL TYPE; CONTROLLED STUDY; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN PURIFICATION; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CAMELS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOGLOBULIN G; LIVER NEOPLASMS; MILK; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84866150604     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-201     Document Type: Article

References (51)

1. Efficient initiation of HCV RNA replication in cell culture. Blight KJ, Kolykhalov AA, Rice CM, Science 2000 290 1972 74 10.1126/science.290.5498.1972 11110665
2. Camel milk: an alternative for cow's milk allergy in children. Ehlayel MS, Hazeima KA, Al-Mesaifri F, Bener A, Allergy Asthma Proceeding 2011 32 255 8 10.2500/aap.2011.32.3429
3. Consumption of camel milk by patients intolerant to lactose. A preliminary study. Cardoso RR, Santos RM, Cardoso CR, Carvalho MO, Review Allergy Mexican 2010 57 26 32
4. Anaphylaxis to camel milk in an atopic child. Al-Hammadi S, El-Hassan T, Al-Reyami L, Allergy 2010 65 1623 1625 10.1111/j.1398-9995.2010.02421.x 20560906
5. Beneficial effect of camel milk in diabetic nephropathy. Agrawal RP, Dogra R, Mohta N, Tiwari R, Singhal S, Sultania S, Acta Biomedica 2009 80 131 134
6. Camel milk as an adjuvant therapy for the treatment of type 1 diabetes: verification of a traditional ethnomedical practice. Mohamad RH, Zekry ZK, Al-Mehdar HA, Salama O, El-Shaieb SE, El-Basmy AA, et al. Journal Medical Food 2009 12 461 5 10.1089/jmf.2008.0009
7. Zero prevalence of diabetes in camel milk consuming Raica community of north-west Rajasthan, India. Agrawal RP, Budania S, Sharma P, Gupta R, Kochar DK, Panwar RB, Sahani MS, Diabetes Research Clinical Practice 2007 76 290 6 10.1016/j.diabres.2006.09.036
8. Effects of milk-derived bioactives: an overview. Shah NP, British Journal Nutrition 2000 84 3 10
9. Effect of heat treatment on camel milk proteins with respect to antimicrobial factors: a comparison with cow's and buffalo milk. El-Agamy EI, Food Chemistry 2000 68 227 232 10.1016/S0308-8146(99)00199-5
10. Preliminary observations on lactoferrin secretion in human vaginal mucus: variation during the menstrual cycle, evidence of hormonal regulation, and implications for infection with Neisseria gonorrhoeae. Cohen MS, Britigan BE, French M, Bean K, American Journal Obstetrics & Gynecology 1987 157 1122 25 23090537
11. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. Harmsen MC, Swart PJ, de Bethune MP, Pauwels R, De Clercq E, Journal Infectious Diseases 1995 172 380 88 10.1093/infdis/172.2.380
12. Lactoferrin-a multifunctional protein with antimicrobial properties. Farnaud S, Evans RW, Molecular Immunology 2003 40 395 405 10.1016/S0161-5890(03) 00152-4 14568385
13. Biological role of lactoferrin. Sánchez L, Calvo M, Brock JH, Archive Diseases Children 1992 67 657 61 10.1136/adc.67.5.657
14. Effect of heat treatment on bovine lactoperoxidase activity in skim milk: kinetic and thermodynamic analysis. Marín E, Sánchez L, Pérez MD, Puyol P, Calvo M, Journal Food Science 2003 68 89 93 10.1111/j.1365-2621.2003.tb14120.x
15. Naturally occurring antibodies devoid of light chains. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Nature 1993 363 446 48 10.1038/363446a0 8502296
16. Isolation and identification of three bactericidal domains in the bovine -lactalbumin molecule. Pellegrini A, Thomas U, Bramaz N, Hunziker P, von Fellenberg R, Biochimica Biophysica Acta 1999 1426 439 48 10.1016/S0304-4165(98) 00165-2
17. A folding variant of -lactalbumin with bactericidal activity against Streptococcus pneumonia. Håkansson A, Svensson M, Mossberg AK, Sabharwal H, Linse S, Lazou I, Lonnerdal B, Svanborg C, Molecular Microbiology 2000 35 589 600 10672181
18. Enzymatic digestion and antioxidant activity of the native and molten globule state of camel -lactalbumin: possible significance for use in infant formula. Salami M, Yousefi R, Ehsani MR, Razavi SH, Chobert JM, Haertlé T, Saboury AA, Atri MS, Niasari-Naslaji A, Ahmad F, Moosavi-Movahedi AA, International Dairy Journal 2009 19 518 23 10.1016/j.idairyj.2009.02.007
19. Composition and characteristics of camel milk. Farah Z, Journal Dairy Research 1993 60 603 626 10.1017/S0022029900027953
20. Antimicrobial activity of camels milk against pathogenic strains of Escherichia coli and Listeria monocytogenes. Benkerroum N, Mekkaoui M, Bennani N, Hidane K, International Journal Dairy Technology 2008 57 39 43
21. Lactoferrin research, technology and applications. Wakabayashi H, Yamauchi K, Takase A, International Dairy Journal 2006 16 1241 1251 10.1016/j.idairyj.2006.06.013
22. Compositional technological and nutritional aspects of dromedary camel milk. OA Ah, Al Kanhal HA, Int Dairy J 2010 20 811 821 10.1016/j.idairyj.2010. 04.003
23. Examination of the Activity of Camel Milk Casein against Hepatitis C Virus (Genotype-4a) and Its Apoptotic Potential in Hepatoma and HeLa Cell Lines. Almahdy O, EL-Fakharany EM, EL-Dabaa E, Ng TB, Redwan EM, Hepatitis Monthly 2011 11 724 730 10.5812/kowsar.1735143X.1367 22235215
24. Apoptosis induced by a human milk protein. Håkansson A, Zhivotovsky B, Orrenius S, Sabharwal H, Svanborg C, Proceeding National Academy of Science U S A. 1995 92 8064 8068 10.1073/pnas.92.17.8064
25. Apoptosis and tumor cell death in response to HAMLET (human -lactalbumin made lethal to tumor cells). Hallgren O, Aits S, Brest P, Gustafsson L, Mossberg AK, Wullt B, Svanborg C, Advance In Experimental Medicine Biology 1998 606 217 240
26. Changes in proteasome structure and function caused by HAMLET in tumor cells. Gustafsson L, Aits S, Onnerfjord P, Trulsson M, Storm P, Svanborg C, PLoS ONE 1995 4 5229
27. Antiviral compounds derived from naturally occurring proteins. Pellegrini A, Engles M, Current Medical Chemistry 2005 4 55 66
28. Camel lactoferrin markedly inhibits hepatitis C virus genotype 4 infection of human peripheral blood leukocytes. Redwan EM, Tabll A, J Immunoassay Immunochemistry 2007 28 267 77 10.1080/15321810701454839
29. Inhibitory Effects of Native/Recombinant Full-Length Camel Lactoferrin and its N/C lobes on Hepatitis C Virus Infection of Huh7.5 Cells. Liao Y, El-Fakharany E, Lönnerdal B, Redwan EM, Journal Medical Microbiology 2012 61 375 383 10.1099/jmm.0.033894-0
30. Potential activity of camel milk-amylase and lactoferrin against hepatitis c virus infectivity in HepG2 and lymphocytes. EL-Fakharany EM, Tabll A, Redwan EM, Hepatitis monthly 2008 8 101 9
31. Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. Nozaki A, Ikeda M, Naganuma A, Nakamura T, Inudoh M, Tanaka K, Kato N, Journal Biological Chemistry 2003 278 10162 10173 10.1074/jbc.M207879200
32. Affinity selection of a camelized VH domain antibody inhibitor of hepatitis C virus NS3 protease. Martin F, Volpari C, Steinkuhler C, Dimas N, Protein Engineering 1997 10 607 614 10.1093/protein/10.5.607 9215580
33. Domain antibodies: proteins for therapy. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM, Trends In Biotechnology 2003 21 484 490 10.1016/j.tibtech.2003.08.007 14573361
34. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Hölzer W, De Genst E, Wyns L, Muyldermans S, EMBO Journal 1998 17 3512 3520 10.1093/emboj/17.13.3512 9649422
35. Biochemical and immunological properties of four intravenous Immunoglobulin G preparations. Redwan EM, Human Antibodies 2002 11 79 84 12454368
36. Prevalence of tetanus immunity in the Egyptian population. Redwan EM, EL-Awady MK, Human Antibodies 2002 11 55 59 12237476
37. Animal-derived pharmaceutical proteins. Redwan EM, J Immunoassay Immunochemistry 2009 30 262 290 10.1080/15321810903084400
38. Cumulative updating of approved biopharmaceuticals. Redwan EM, Human Antibodies 2007 16 137 158 18334749
39. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MY, Alter HJ, Feinstone SM, Proceeding National Academy of Science USA 2007 104 8449 8454 10.1073/pnas.0703039104
40. Ovine anti-rabies antibody production and evaluation. Redwan EM, Fahmy A, Hanafy AE, EL-Baky NA, Sallam SM, Comparative Immunology Microbiology & Infectious Diseases 2009 32 9 19 10.1016/j.cimid.2007.11.004 23084582
41. Flow cytometric detection of hepatitis C virus antigens in infected pripheral blood leukocytes: binding and entry. EL-Awady MK, Tabll AA, Redwan EM, Youssef S, Omran MH, El-Demellawy M, World Journal Gastroenterology 2005 11 5203 5208
42. HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. EL-Awady MK, Tabll AA, El-Abd YS, Bahgat MM, Shoeb HA, Youssef SS, NG Be-D, Redwan E-RM, El-Demellawy M, Omran MH, El-Garf WT, Goueli SA, World Journal Gastroenterology 2006 12 4836 4842
43. Oyster mushroom laccase inhibits hepatitis C virus entry into peripheral blood cells and hepatoma cells. El-Fakharany EM, Haroun BM, Ng TB, Redwan EM, Protein & Peptide Letter 2010 17 1031 1039 10.2174/092986610791498948 23094262
44. A rapid sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Bradford MM, Analytical Biochemistry 1976 72 248 254 10.1016/0003-2697(76)90527-3 942051
45. Simple, sensitive and quick protocol to detect less than 1ng of bacterial lipopolysaccharide. Redwan EM, Preparative Biochemistry Biotechnology 2012 42 171 182 10.1080/10826068.2011.586081 22394065
46. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Fields GB, Noble RL, International Journal Peptide & Protein Research 1990 35 161 214 23091570
47. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a and 6a. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, Wlliams R, Lau YJ, Journal Clinical Microbiology 1997 35 201 207
48. Efficacy comparison of gel-based, membrane and glass array techniques to detect human antibodies isotypes among the Egyptian HCV-patients. EL-Baky NA, Omar SH, EL-Badry H, Redwan EM, Human Antibodies 2008 17 63 71 19029663
49. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Mosmann T, Journal Immunological Methods 1983 65 6 24
50. The anti-cancer activity of human consensus interferon-alpha synthesized in cell-free system. El-Baky NA, Omar SH, Redwan EM, Protein Expression and Purification 2011 80 61 67 10.1016/j.pep.2011.07.003 21802515
51. Expression, purification, and characterization of recombinant human consensus interferon-alpha in Escherichia coli under p(L) promoter. Mohammed Y, El-Baky NA, Redwan EM, Preparative Biochemistry and Biotechnology 2012 42 426 447 10.1080/10826068.2011.637600 22897766